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Abstract
Background: Triester glycerol oxide gel (Protefix® Queisser Pharma, Germany) is a new topical agent that has 
the property of adherence to the oral mucosa by forming a lipid film which protects against mechanical trauma 
and may help to reduce oral tissue moisture loss and inflammation. The aim of this clinical trial was to determine 
the efficacy of a topical TGO gel and to also compare it with triamcinolone acetonide pomade in the treatment of 
minor recurrent aphthous stomatitis. 
Material and Methods: This study was a randomized, double-blind, placebo-controlled clinical trial and 180 patients 
with the complaint of minor aphthous ulcers were enrolled in this study. The sociodemographic data and clinical 
characteristics of the ulcer were collected by questionnaire. Ulcer size and pain level measurements were performed 
and the efficacy indices for ulcer pain and size were calculated at day 0,2,4,6 by the same investigator.
Results: Significant differences were not detected among the demographics and ulcer histories including age, gen-
der, onset of ulcer, mean healing time, family RAS history and ulcer localization between three groups. The pain 
score in TGO group was found statistically lower at day 2,4, and 6. Efficacy index and improvement rate of TGO 
group, regarding pain score, was higher than the other two groups at day 2 and 4. The reduction in ulcer size was 
statistically higher in TGO group than the other two groups at day 4 and 6.
Conclusions: Topical application of TGO gel could decrease pain intensity, accelerate ulcer healing without any 
side effects, utilizing an easy appliable and accessible procedure. Therefore TGO gel could be a well-tolerated, 
safe, topical therapeutic agent in the clinical practice of RAS treatment.
Key Words: Topical therapy, triester glycerol oxide, triamcinolone acetonide, minor recurrent aphthous stoma-
titis.
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Introduction
Recurrent aphthous stomatitis (RAS) is a multifacto-
rial chronic inflammatory disorder, characterized by 
recurrent, round or ovoid, painful ulcerations of the 
non-keratinized mucosa with a shallow necrotic center 
covered by a pseudomembrane and surrounded by an 
erythematous halo. RAS is divided into three varie-
ties; minor, major and herpetiform of which the most 
common form is the minor variety (1-3). Although the 
episodes are generally transitory and self-limited, the 
symptoms can be disturbing, incapacitating and can af-
fect patient’s quality of life (4). The prevalence of RAS 
is between 5% and 25% in the general population, but 
can be as high as 50% to 60% in different ethnic or so-
cioeconomic groups (1,5). 
Although several local and systemic causative factors 
including stress, local trauma, cessation of smoking, al-
lergic agents, genetic background, infections, hematinic 
deficiencies, immune dysregulation, nutritional defi-
ciencies, hormonal disturbances have been proposed its 
etiology remains unknown (6). RAS has been histologi-
cally characterized by varying degrees of neutrophils 
and mononuclear cell infiltration in the lamina propria 
and the inflammatory process plays an important role 
in RAS. The pain that is experienced might derive from 
the excessive inflammation and physiochemical irri-
tation of afferent nerve endings at the junction of the 
epithelial and subepithelial layers (1,4). Because the de-
finitive etiology and pathogenesis is not entirely under-
stood, there is no specific and reliable therapy and the 
management of RAS still poses a complicated problem 
for both clinicians and patients worldwide.
The current therapeutic approaches aim to relieve pain, 
alleviate inflammation, decrease functional disability, 
promote ulcer healing as well as the reduction of the ul-
cer duration, frequency of recurrences and an increase 
in disease-free period. The best treatment is that which 
will control the ulcers for the longest time with mini-
mum side effects. The treatment modality should be de-
termined by disease severity, patient’s medical history, 
the frequency of flare-ups, size and number of ulcers 
and the patient’s ability to tolerate the medication. Sev-
eral topical medicaments including corticosteroids, an-
tibiotics, local analgesics, astringents, and laser therapy 
have been used for treatment (7,8). Systemic medica-
tions such as colchicine, levamisole, dapsone, thalido-
mide, pentoxifylline have been tried if topical therapy 
is ineffective. Although systemic medications are more 
effective, several side effects limit their long-term and 
extensive usage, therefore topical agents are still the 
first choice of treatment (8,9).
Triamcinolone acetonide (TA) a medium to high po-
tency corticosteroid, is a fluorinated prednisolone de-
rivative, considered an intermediate-acting glucocorti-
coid and available as a cream (0.1%) and as an ointment 
(0.1%) for topical use in medical practice. The absorp-
tion rate varies from 1% to 36% in different parts of the 
body and increases via damaged, inflammed or dressed 
skin. Metabolism of triamcinolone after topical appli-
cation is dermal. The small amount which may enter 
systemic circulation is metabolized in the liver and 
when used in oral cavity, rarely there is a risk to lead 
adverse reactions such as candidiasis and/or atrophy of 
the oral mucosa (2,10). Topical TA ointment was shown 
to be effective in the treatment of aphthous lesions in 
the literature (10,11). Triamcinolone acetonide pomade, 
(Kenacort-A Orabase® Pomade, 0,1% Triamsinolon 
acetonide, Bristol-Myers Squibb Ilacları Inc. Istanbul, 
Turkey) is a slow release glucocorticoid pomade that 
forms a protective layer over the ulceration and exerts 
an anti-inflammatory action and has been used widely 
in aphthous ulcer treatment in Turkey for many years. 
Although new different topical agents were launched 
in recent years and alternative topical medicines with 
decreased side effects are gaining more attention, TA 
pomade is still the most commonly prescribed and best 
known agent in aphthous ulcer treatment for both the 
clinicians and the patients in Turkey.
Triester glycerol oxide (TGO) gel (Protefix® Que-
isser Pharma, Germany) is a topical agent that has the 
property of adherence to the oral mucosa by forming 
a lipid film which protects against mechanical trauma 
and may help to reduce oral tissue moisture loss and 
inflammation (12). Following its use a significant reduc-
tion of the number of erythrocytes and inflammatory 
cells and a significant increase of mature epithelial cells 
of oral mucosa were reported (13). TGO gel also has 
been shown to reduce RAS related symptoms, such as 
pain and was found effective in lengthening the dura-
tion of recurrence time (13). The objective of this rand-
omized, double-blind, placebo-controlled clinical trial 
was to determine the efficacy of a topical TGO gel and 
also compare with TA pomade in the treatment of mi-
nor recurrent aphthous stomatitis in a group of Turkish 
patients.
Material and Methods 
- Materials and Blinding
TA pomade (Kenacort-A Orabase® Bristol-Myers 
Squibb Ilacları Inc. Istanbul, Turkey) contains 0.1% 
triamcinolon acetonide as an active ingredient and 
gelatin, pectin, carboxymethylcellulose sodium in plas-
ticized hydrocarbon gel, a polyethylene and mineral 
oil gel base as an inactive substances. TGO gel (Pro-
tefix® Queisser Pharma, Germany) contains 92.67% 
triester glycerol oxide, where as placebo gel contains 
92.67% corn oil and both gels contain 7% silica, col-
loid anhydrous, 0.2% clove oil, 0.1% saccharin sodium 
and 0.01% peppermint oil. All three agents were packed 
in the same sized, white colored soft tubes of 5g each. 
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A single investigator (F.P) who was blind to the study 
protocol and subjects, randomly numbered these tubes 
and medications. Then, the numbers of the tubes were 
assigned to patients’ numbers by using a computer-gen-
erated number list and the tubes were then delivered to 
the clinical investigators who were blind to the treat-
ment agents.
- Subjects and study design
This study was a randomized, double-blind, placebo-
controlled clinical trial, approved by the Ethical Com-
mittee of Marmara University Faculty of Medicine 
(Project No: 09.2016.116). Based on the inclusion and 
exclusion criteria, 180 patients who were referred to the 
Istanbul University, Faculty of Dentistry, Department 
of Oral and Maxillofacial Surgery with the complaint 
of aphthous ulcers were enrolled in this study and all 
of the participiants received written and verbal infor-
mation about the study and signed a detailed informed-
consent form voluntarily. Randomly allocated subjects 
received one of these three agents; TA pomade, TGO 
gel or placebo gel.
The diagnosis of RAS was based on the anamnesis and 
clinical examination. Participants fullfilled the follow-
ing inclusion criteria; being willing to participate in the 
study and signed the informed consent form; being be-
tween the ages of 18 and 65; having a history of RAS 
for at least two years with a frequency of at least one 
outbreak every two months; having only one well-de-
marcated ulcer in an easily accessible area of the mouth 
for less than 48 hours’ duration and reporting pain sen-
sation without any anesthesia or paresthesia. 
The exclusion criteria were as follows; pregnancy and 
lactation; having a hematological deficiency such as ane-
mia, iron, vitamin B12 and/or folic acid deficiency that 
could pose a risk for RAS; systemic diseases such as ul-
cerative colitis, Crohn’s disease, Behçet’s syndrome in 
which RAS is part of their clinical presentation; alcohol 
and smoking consumption; allergy history; treatment 
of ulcers with systemic steroids, vitamins, antibiotics, 
antihistamines, oral retinoids or immunomodulatory 
agents within three months before study entry; and use 
of nonsteroidal anti-inflammatory drugs or mouthwash 
for ulcer treatment prior to 72 hours of study entry.
The sociodemographic data and clinical characteristics 
of the ulcer were collected by questionnaire regarding 
age, gender, the mean disease duration (onset of ul-
cer), the mean healing time of previous ulcers, genetic 
background including family RAS history, and the lo-
calization of the current ulcer. Ulcer size was calculated 
as follows; the distance between two opposite outside 
edges of the white border was measured by using a cali-
brated periodontal probe with milimeter markings. Two 
measurements approximately 90 degrees from each 
other were obtained and then multiplied to present the 
cross-sectional area of the ulcer. To evaluate pain level, 
a visual analog scale (VAS) consisting of a 10-cm hori-
zontal line between the poles of “no pain (0)” to “un-
bearable pain (10)” was used. Patients were requested to 
mark the line with a vertical mark at the point that best 
represented the present pain level of the ulcer (14). Ulcer 
size and pain level measurements were recorded by the 
same investigator (D.O) in all patients at each appoint-
ment (Day 0,2,4,6). 
The efficacy indices (EI) for ulcer pain and size were 
calculated using the following formula; Vx referring to 
values measured at determined days (in this study, at 
days 2,4 and 6) by the investigator and V1 referring to 
the baseline value measured at day 0.
EI=[(Vx-V1) ÷V1]×100% (4,15).
Efficacy indices (EI) were evaluated on a 4-rank scale:1)
healed; EI ≥95%, 2)marked improvement; EI ≥70% to 
<95%, 3)moderate improvement; EI ≥30% to <70%, 4)
no improvement; EI <30%.
Evaluation of marked improvement rate (MIR) referred 
to (1)+(2) (EI ≥ 70%) while evaluation of improvement 
rate (IR) referred to (1)+(2)+(3) (EI ≥ 30%) (14).
After questionnaire form was filled out and clinical ex-
amination was carried out, the ulcer size and pain were 
measured by the same investigator (D.O) in all patients 
before the first application of the agents (day 0). Then 
another investigator (S.E) who was blind to the group 
and agent assignment, applied the chosen agent to the 
ulcer to show the correct application of the agent. All 
patients were instructed to rinse their mouth with tap 
water prior to the administration of the agent and ap-
ply the agent to the ulcer 4 times per day (after meals 
and before bed time) for 7 days (day 0 to day 6) and 
it was recommended not to eat or drink anything for 
30 minutes after application of the agent in all groups. 
The participants were requested to visit our clinic on the 
morning (9-11 am) of days 2,4 and 6 for ulcer size and 
pain evaluation and strictly warned not to use any other 
products for the treatment of aphthous ulcers while par-
ticipating in this study. At the end of therapy, all pa-
tients were also asked to report any adverse effects of 
the agents.
- Statistical analyses
The sample size was determined using G*Power 3.0.10 
software. A total of 29 ulcer per group were chosen con-
sidering Power: 0.80, a:0.05, effect size: 0.339 and SD: 
2 for pain score. All of the data was analyzed with IBM 
SPSS Statistics 22.0 software program and significance 
was evaluated at a level of p<0.05. During the assessment 
of the study data, conformity of the parameters to the nor-
mal distribution was assessed by the Shapiro Wilks test. 
During the evaluation of the study data, regarding the 
comparisons of quantitative data as well as descriptive 
statistical methods (Mean, Standard deviation), One-way 
Anova test was used for the intergroup comparisons of 
parameters with normal distribution and Tukey HDS test 
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was used for the determination of the group causing dif-
ference. Kruskal Wallis test was used for the intergroup 
comparisons of parameters without normal distribution 
and Mann Whitney U test was used for the determination 
of the group causing difference. Paired Samples t test was 
used for the in-group comparisons of parameters with 
normal distribution. Wilcoxon Signed Ranks test was 
used for the in-group comparisons of parameters without 
normal distribution. Chi-Square test was used for com-
parison of qualitative data.
Results
A total of 180 patients were enrolled in the study and 20 
patients dropped out due to violations of the study pro-
tocol therefore 53 subjects in TA group, 56 subjects in 
TGO group and 51 subjects in placebo group completed 
the study (total 160). We evaluated demographic and ef-
fectiveness datas excluding these subjects. Statistically 
significant differences were not detected among the de-
mographics and ulcer histories including age, gender, 
onset of ulcer, mean healing time, family RAS history 
and ulcer localization between three groups (p>0.05). 
51.3% (n=82) were females and 48.8% (n=78) were 
males. The age of participants ranged between 18-65 
and the mean age was 38.76±13.03 years.
- Moderation of pain
Although the mean ulcer pain scores of three groups 
matched well at study entry (p>0.05), significant group 
differences were found at the later visits (day 2,4,6) 
(p<0.01). The ulcer pain scores (VAS) of three groups 
decreased with time however, the pain score in TGO 
group was statistically lower than that of the TA and 
placebo groups at days 2,4 and 6 (p<0.01), there was no 
significant difference between TA and placebo groups 
(p>0.05) (Table 1, Fig. 1).
On the second day, the efficacy index of the TGO group 
was found much greater than that of TA and placebo 
groups (p<0.01). Also there was a significant difference 
between TA group and placebo group (p:0.001; p<0.01). 
The TGO group had a significantly higher “improve-
ment rate” (10.7% vs 0%,p<0.003) when compared with 
TA and placebo groups whereas there was no significant 
difference between TA and placebo groups (p>0.05) 
(Table 2).
On the fourth day, the efficacy index of the TGO group 
was found much greater than that of TA and placebo 
groups (p<0.01) and had a significantly higher “im-
provement rate” (92.9% vs 71.7% and 52.9%%, p<0.001) 
when compared with TA and placebo groups. The effi-
cacy index and “improvement rate” of TA group was 
significantly higher than that of placebo group (p<0.05) 
(Table 2).
VAS
TA group
(n=53)
TGO group
(n=56)
Placebo group
(n=51) 1p
Mean±SD (Medi-
an)
Mean±SD (Medi-
an)
Mean±SD (Medi-
an)
Day 0 8,63±1,09 (9) 8,45±1,03 (8,5) 8,35±1,15 (8,5)           0,434
Day 2 7,4±1,05 (7) 6,48±0,86 (6,5) 7,57±0,98 (8) 0,001**
Day 4 5,84±1,04 (6) 4,83±0,96 (5) 5,94±0,94 (6) 0,001**
Day 6 3,15±1,05 (3) 2,33±1,03 (2,5) 3,26±1 (3)  0,001**
Day 0-Day 2 2p 0,001** 0,001** 0,001**
Day 0-Day 4 2p 0,001** 0,001** 0,001**
Day 0-Day 6 2p 0,001** 0,001** 0,001**
Table 1. Comparison of mean ulcer pain scores among the three groups.
Fig. 1. Comparison of mean ulcer pain scores among the three groups.
1 Kruskal Wallis Test  2 Wilcoxon sign test ** p<0.01
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On the sixth day, the number of patients whom totally 
healed (8.9% vs 1.9% and 2%) and showed marked im-
provement (46.4% vs 28.3% and 13.7%) in TGO group 
were statistically higher than the TA and placebo groups 
(p<0.05; p<0.01) whereas no statistically significant 
difference was found between TA and placebo groups 
(p>0.05). TGO group sustained a significantly higher 
efficacy index (p<0.01) but there was no significant 
difference between TA and placebo groups in terms of 
efficacy index (p>0.05). The “improvement rate” was 
similar in all groups but “marked improvement rate” of 
TGO group was found statistically higher than that of 
TA and placebo groups (p<0.01) (Table 2).
- Reduction in ulcer size
There was no significant difference among mean ulcer 
sizes of three groups at study entry and on the second 
day (p>0.05); but significant group differences ap-
peared at day 4 and 6 (p<0.01). The mean ulcer size in 
TGO group was statistically lower than that of the TA 
and placebo groups at day 4 and 6 (p<0.01), while there 
was no significant difference between TA and placebo 
groups (p>0.05) (Table 3, Fig. 2).
On the second day, the efficacy index of the TGO group 
was found much greater than placebo group (p:0.001; 
p<0.01) but there was no significant difference between 
other groups (p>0.05). Although the “improvement 
rate” was similar in all groups (p>0.05) (Table 4).
On the fourth day, the efficacy index of the TGO group 
was found much greater than that of other groups 
(p<0.01) and had a significantly higher “improvement 
rate” (98.2% vs 86.8% and 70.6%, p<0.001) when com-
pared with TA and placebo groups. There were no sig-
nificant differences between TA and placebo groups 
in terms of efficacy index and “improvement rate” 
(p>0.05) (Table 4).
On the sixth day, compared with TA and placebo groups, 
the TGO group maintained a significantly higher effica-
cy index (p<0.01) whereas a significant difference was 
found between TA and placebo groups (p:0.045;p<0.05) 
(Table 4). Although the “improvement rate” was similar 
in all groups (p>0.05) “marked improvement rate” of 
TGO group was found statistically higher than that of 
other groups (p<0.01) and there was no difference be-
tween TA and placebo groups (p>0.05) (Table 4).
VAS 
 Day 2    Day 4    Day 6   
TA group 
(n=53) 
TGO group 
(n=56) 
Placebo 
group 
(n=51) 
p 
TA group 
(n=53) 
TGO 
group 
(n=56) 
Placebo 
group 
(n=51) 
p 
TA group 
(n=53) 
TGO group 
(n=56) 
Placebo 
group 
(n=51) 
p 
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
(1)Heal 0 (%0) 0 (%0) 0 (%0) 
 
10,003** 
0 (%0) 0 (%0) 0 (%0)  1 (%1,9) 5 (%8,9) 1 (%2,0)  
(2)Marked 
improvement 
0 (%0) 0 (%0) 0 (%0) 0 (%0) 0 (%0) 0 (%0) 
10,001** 
15 (%28,3) 26 (%46,4) 7 (%13,7) 
10,001** 
(3)Moderate 
improvement 
0 (%0) 6 (%10,7) 0 (%0) 38 (%71,7) 52 (%92,9) 27 (%52,9) 37 (%69,8) 25 (%44,6) 43 (%84,3) 
(4)No 
improvement 
53 (%100) 50 (%89,3) 
51 
(%100) 
15 (%28,3) 4 (%7,1) 24 (%47,1) 0 (%0) 0 (%0) 0 (%0) 
Marked 
Improvement 
Rate 
0 (%0) 0 (%0) 0 (%0) - 0 (%0) 0 (%0) 0 (%0) - 16 (%30,2) 31 (%55,4) 8 (%15,7) 0,001** 
Improvement 
Rate 
0 (%0) 6 (%10,7) 0 (%0) 10,003** 38 (%71,7) 52 (%92,9) 27 (%52,9) 10,001** 53 (%100) 56 (%100) 51 (%100) 11,000 
Efficacy Index 
Ort±SS 
14,34±5,42 23,18±5,47 9,03±6,76 20,001** 32,61±6,43 42,85±9,19 28,63±8,12 20,001** 63,96±10,59 
72,86±11,3
2 
61,21±10,4
4 
20,001** 
 1Ki-kare test 2 Oneway ANOVA Test ** p<0.01
Table 2. Efficacy of VAS reduction.
Ulcer Size
TA group
(n=53)
TGO group
 (n=56)
Placebo group
(n=51) 1p
Mean±SD Mean±SD Mean±SD 
Day 0 24,83±4,54 25,38±4,52 25,23±3,8 0,797
Day 2 21,21±3,95 21,17±4,06 22,06±3,67 0,421
Day 4 15,52±3,65 13,74±3,64 16,52±3,65 0,001**
Day 6 7,5±2,82 5,79±2,53 8,65±2,66 0,001**
Day 0-Day 2 2p 0,001** 0,001** 0,001**
Day 0-Day 4 2p 0,001** 0,001** 0,001**
Day 0-Day 6 2p 0,001** 0,001** 0,001**
1Oneway ANOVA Test 2Paired Sample t test **
Table 3. Comparison of ulcer size among the three groups.
Med Oral Patol Oral Cir Bucal-AHEAD OF PRINT - ARTICLE IN PRESS                                                                                              Triester Glycerol Oxide gel in the treatment of minor RAS
All patients tolerated the agents and no side effect were 
reported during the study. Only 5 patients in TA group 
(9.43%) mentioned some difficulties in the application 
of the agent.
Discussion
RAS is a complicated condition and the precise etiol-
ogy still remains unknown. High frequency, worldwide 
distribution, wide age range, recurrent character of the 
disease and decreased quality of life of RAS patients 
have lead to a great deal of research into the etiology 
and treatment of this condition. Various treatment mo-
dalities, topical and systemic agents have been evalu-
ated in different countries for many years (9). Although 
the exact mechanism of TGO in the treatment of RAS 
remains to be clarified, adherence to the oral mucosa by 
forming a lipid film protects against mechanical trauma 
and helps to reduce inflammation. The results of this 
study showed that TGO gel is benefical in pain relief, ul-
cer size reduction and the promotion of healing without 
any systemic or local side effects. 
As known the first line treatment of RAS should always 
start with topical medications such as oral rinses, gels, 
patches, tablets or adhesive films which provide antisep-
tic, anti-inflammatory and analgesic effects (2,3,16,17). 
The most important agents in RAS treatment are topical 
corticosteroids. TA dental paste is a popular agent and 
is being widely used in the treatment of mild to severe 
RAS lesions at different concentrations ranging 0.05%-
0.5% (the most effective concentration to be 0.1%) 3-10 
times a day (2,18,19).
Several studies comparing the efficiency of different 
agents with TA were reported in the literature. Desh-
mukh and Bagewadi have compared the efficacy of 
curcumin, which is known for its strong antioxidant, 
antiseptic, antibacterial, anti-inflammatory, immu-
nomodulatory and analgesic properties, and TA in the 
Fig. 2. Comparison of ulcer size among the three groups.
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gel form in the treatment of RAS and they found similar 
reduction in size and number of ulcer in both groups 
(20). Bhalang et al. reported a higher effectiveness of 
0.1% TA than acemannan, a polysaccharide extracted 
from Aloe vera, in the treatment of oral aphthous ulcer-
ation (21). Comparing TA 0.025% with chlorhexidine 
0.12% applied topically, covered by a barrier of isobutyl 
cyanoacrylate, in the treatment of RAS, a controlled, 
randomized clinical study found a very significant dif-
ference in the reduction of the intensity and the percep-
tion of pain on different days when the two groups with 
medication were compared with the control group, but 
the difference was not significant when the two medi-
cines were compared (18,22). 
Hyaluronic acid (HA) gel is an alternative agent for 
topical treatment. The topical application of 0.2% HA 
gel seems to be an effective and safe therapy in pa-
tients with RAS (23). Different lasers were also used 
for RAS treatment, Tezel et al. (24) have suggested that 
the Nd:YAG laser has better patient acceptance, shorter 
treatment time, lower rates of pain and post-treatment 
adverse events among patients with RAS. Lalabonova 
et al. reported that to use low-level laser therapy for 
treatment of chronic RAS was better than those ob-
tained in the group receiving pharmacotherapy. Pain 
and inflammation have been very effectively managed 
with LLLT and epithelization has been considerably ac-
celerated (25).
Although several treatment modalities have been tried, 
RAS is one of the most common oral mucosal disease 
in Turkey and it still poses a complicated problem for 
both the clinicians and patients. In our study, as an al-
ternative to TA pomade, a randomized, double-blind, 
placebo-controlled clinical trial has investigated the 
effectiveness of TGO gel (Protefix® Queisser Pharma, 
Germany) in the treatment of minor RAS. The results 
demonstrated that TGO gel not only resolved the pain of 
the patients but also reduced the ulcer size with no sys-
temic or local side effects. Furthermore TGO gel was 
easy to use without any unfavorable taste and was easy 
for patients to apply. In this study, 10.7% of the patients 
who used TGO gel showed a moderate improvement in 
pain intensity within 2 days of the start of treatment, 
whereas in the TA and control group, none of the pa-
tients showed moderate improvement in the same peri-
od. The pain score in TGO group was statistically lower 
than that of the TA and placebo groups at day 2,4 and 
6 whereas there was no significant difference between 
TA and placebo groups. Although the baseline ulcer 
size was similar in three groups at the beginning of the 
study, significant differences were detected after 4 days. 
The reduction in ulcer size of the TGO group was found 
much greater at day 4 and 6 when compared with TA 
and placebo groups. These results showed the efficacy 
of TGO gel in pain and ulcer size reduction.
Some curative effect for pain relief was also observed 
in placebo group which may be caused from the protec-
tive film layer produced by the placebo gel because it 
isolates the physical and chemical stimuli and promotes 
the healing process. Because all the patients were blind 
to the therapeutic agents, placebo may have also caused 
some psychologic effects. According to our knowledge 
this is the first randomized, double-blind, placebo-con-
trolled clinical trial investigating the effects of TGO gel 
in the treatment of RAS. In a placebo controlled study, 
the efficacy of TGO gel in the treatment of the ulcera-
tions related to new complete denture have been inves-
tigated and TGO gel found ineffective (13). 
Given the inflammatory nature of RAS, our interpre-
tation of these results is that the clinical beneficial ef-
fects of the TGO gel could be attributed to the ability 
to decrease inflammation and increase epithelization. 
Because we did not perform a cytological examination 
we could not know the exact role of TGO in the heal-
ing process of an ulcer. Further studies involving larger 
number sample sizes and evaluating the effect of TGO 
in a cellular base are recommended to clarify the mech-
anism and the efficacy of RAS on recurrence.
In conclusion, the present study findings demonstrate 
that topical application of TGO gel could decrease pain 
intensity, accelerate ulcer healing without any side ef-
fects and with an easily appliable and accessible proce-
dure. Therefore TGO gel could be a well-tolerated, safe, 
topical therapeutic agent in clinical practice of RAS 
treatment.
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